

Supplementary Table. Registered ongoing clinical trials for different CML interventions (ClinicalTrials.gov)

Clinical trials identifier	Study start date	Title	Intervention/ Drug	Phase
NCT05701215	Jul 2023 (Estimated)	Venetoclax After TKI to Target Persisting Stem Cells in CML	Venetoclax	II
NCT04808115	May 2023 (Estimated)	A Phase I Trial of Incorporating Natural Killer (K-NK) Cells for Patients With CML and Molecular Residual Disease After Tyrosine Kinase Inhibitor (TKI) Therapy	KDS-1001	I
NCT05384587	Nov 2022	A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd and 1st Line Chronic Phase - Chronic Myelogenous Leukemia (ASC2ESCALATE)	Asciminib	II
NCT05456191	Nov2022	A Phase IIIb, Multi-center, Open-label, Randomized Study of Tolerability and Efficacy of Oral Asciminib Versus Nilotinib in Patients With Newly Diagnosed Philadelphia Chromosome Positive CML in Chronic Phase.	Asciminib Nilotinib	III
NCT05304377	May 2022	A Phase 1a/1b Study of ELVN-001 for the Treatment of CML.	ELVN-001	I
NCT05367765	Apr 2022	Evaluating the Efficacy and Safety of Flumatinib Versus Imatinib for in Patients With Newly Diagnosed Chronic Myeloid Leukemia (CML)-in Chronic Phase (CP): A Multicenter, Open-label, Real World Study	Flumatinib Imatinib	IV
NCT05367700	Apr 2022	A Phase I, Open-label, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Single and Multiple Doses of Oral Administration of HS-10382 in Patients With CML.	HS-10382(Part 1: Dose escalation) HS-10382(Part 2: Dose expansion)	I
NCT05376852	Dec 2021	Decitabine and HQP1351-based Chemotherapy Regimen for the Treatment Advaof nced CML	Combination Product: Decitabine and Olverembatinib (HQP1351) chemotherapy	II
NCT05353205	Nov 2021	A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.	Flumatinib	IV
NCT04971226	Oct 2021	A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase	Asciminib Imatinib Nilatinib Bosutinib Dasatinib	III
NCT05007873	Oct 2021	Phase II Study Assessing Safety and Clinical Activity of the Combination of ASTX727 With Dasatinib in Patients With Newly Diagnosed in CML in chronic phase (CML-CP)	Dasatinib Decitabine Cedazuridine	II
NCT04933526	Jul 2021	The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in Patients With CML in chronic phase: an Randomized Controlled Trial.	Flumatinib Dasatinib	IV
NCT04835584	May 2021	An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With a Tyrosine Kinase Inhibitor (TKI) in Patients With Relapsed or Refractory Ph+ CML	KRT-232 Dasatinib Nilotinib	I II

Contd...

Clinical trials identifier	Study start date	Title	Intervention/ Drug	Phase
NCT04666259	May 2021	An Open Label, Multi-center Phase IIIb Study of Asciminib (ABL001) Monotherapy in Previously Treated Patients With CML in chronic phase (CML-CP) With and Without T315I Mutation	ABL001	III
NCT05434312	Mar 2021	A Single-arm, Open-label, Dose Escalation and Dose Expansion Phase 1 Trial to Determine the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TGRX-678 in Patients With Refractory or Advanced CML	TGRX-678	I
NCT04709731	Feb 2021	Cardiovascular Assessment of Ponatinib as Third-Line Treatment Option in CP-CML After Failure of Imatinib and Bosutinib (CarPAs)	Ponatinib	II
NCT04258943	Apr 2020	A Phase I/II Study of Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia”, Study ITCC-054/COG-AAML1921	Bosutinib	I/II
NCT03610971	Nov 2019	Treatment-Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors in CP-CML Patients Who Relapsed After a Prior Attempt at TKI Discontinuation	Ruxolitinib BCR-ABL Tyrosine Kinase Inhibitor (TKI)	II
NCT03895671	Jun 2019	Open-label phase 2 study on the efficacy and tolerance of a combination of Ponatinib and 5-Azacitidine in CML in accelerated phase or myeloid blast crisis - Ponaza trial	Ponatinib Azacitidine	II
NCT03831776	Mar 2019	A study of efficacy and safety of long-acting low dose Ropoginterferon in patients with CML treated with Bosutinib from Diagnosis: a randomized prospective trial	Bosutinib Ropoginterferon	II
NCT03654768	Oct 2018	A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination With BCR-ABL Tyrosine Kinase Inhibitors in CML Patients With Molecular Evidence of Disease	Bosutinib Dasatinib Laboratory Biomarker Nilotinib Ruxolitinib Imatinib	II
NCT03455517	Oct 2018	Activity and Safety of Front-line venetoclax and Rituximab Association (VeRiTAs) in Young and Fit Patients With Chronic Lymphocytic Leukemia (CLL) and Unmutated IGVH and/or Disrupted TP53. A Phase 2 Multicenter Study	Venetoclax Rituximab	II
NCT03595917	Jul 2018	A Phase 1 study of ABL001 in combination with Dasatinib and Prednisone in patients with BCR-ABL positive (BCR-ABL+) B-cell Acute Lymphoblastic Leukemia (B-ALL) and CML	ABL001 Dasatinib Prednisone	I
NCT02629692	Apr 2017	A Two-Part Phase 1/2 Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706, a Novel Tyrosine Kinase Inhibitor (TKI), in Healthy Subjects and Subjects With CML or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)	Vodobotinib (K0706) capsules	I II
NCT02767063	Jul 2016	Candidate therapies in combination or sequentially with Tyrosine Kinase Inhibitors in chronic phase- CML patients in CCR without achieving a deep molecular response: an adaptive trial based on a drop loser design	Pioglitazone Avelumab	I II